Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Cash & Equivalents (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Cash & Equivalents for 4 consecutive years, with $48.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 26.2% to $48.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.9 million through Dec 2025, up 26.2% year-over-year, with the annual reading at $48.9 million for FY2025, 26.2% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $48.9 million at Spruce Biosciences, up from $10.7 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $98.8 million in Q3 2023, with the low at $10.7 million in Q3 2025.
  • Average Cash & Equivalents over 4 years is $52.2 million, with a median of $48.1 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 356.38% in 2023, then tumbled 82.23% in 2025.
  • Over 4 years, Cash & Equivalents stood at $24.5 million in 2022, then soared by 293.43% to $96.3 million in 2023, then crashed by 59.77% to $38.8 million in 2024, then rose by 26.2% to $48.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $48.9 million, $10.7 million, and $16.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.